Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus MENRIUM 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus MENRIUM 5 4.
CENTRAX vs MENRIUM 5-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an anticholinergic that blocks muscarinic acetylcholine receptors.
10-30 mg orally, 3-4 times daily.
1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 3 to 4 times daily before meals and at bedtime. Maximum dose: 8 tablets per day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Chlordiazepoxide: Terminal half-life 5-30 hours (mean 10 hours), extended to 30-60 hours in elderly or hepatic impairment. Clidinium: Terminal half-life approximately 1-2 hours due to rapid clearance.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Chlordiazepoxide: Renal excretion of unchanged drug (<1%) and conjugates (60-70%); fecal excretion (30-40%). Clidinium: Primarily renal elimination as unchanged drug and metabolites (50-70%), with biliary/fecal excretion (30-50%).
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination